Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.70 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | CCR8 | P51685 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900326 | 0.82 | LTA4H (1.00) | LTA4HEGFRKCNH2HRH3 | |
| SCHEMBL14204682 | 0.79 | LTA4H (0.83) | LTA4HEGFRKCNH2HRH3CCR8 | |
| SCHEMBL7138308 | 0.77 | LTA4H (0.74) | LTA4HEGFRKCNH2HRH3ALDH1A1 | |
| SCHEMBL5175350 | 0.77 | LTA4H (0.82) | LTA4HEGFRKCNH2HRH3ALDH1A1 | |
| SCHEMBL8637106 | 0.77 | LTA4H (0.44) | LTA4HCCR8PKMNPSR1ALDH1A1 | |
| SCHEMBL1414283 | 0.77 | ALDH1A1 (0.67) | LTA4HEGFRCCR8PKMNPSR1 | |
| SCHEMBL7139525 | 0.76 | LTA4H (0.80) | LTA4HEGFRKCNH2HRH3CCR8 | |
| SCHEMBL608528 | 0.74 | ALDH1A1 (0.76) | CCR8PKMNPSR1ALDH1A1 | |
| SCHEMBL10460820 | 0.74 | LTA4H (0.73) | LTA4HEGFRKCNH2HRH3CCR8 | |
| SCHEMBL8675902 | 0.74 | LTA4H (0.45) | LTA4HCCR8NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1221441-A2 | LTA4 Hydrolase inhibitors | G.D. SEARLE & CO. (US) | 2002-07-10 | — | — | EP | claimed |
| EP-0804427-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | claimed |
| EP-0786992-A2 | LTA 4? HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1997-08-06 | — | — | EP | claimed |
| US-5585492-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES WHICH ARE MEDIATED BY LTB4 PRODUCTION, SUCH AS PSORIASIS, ULCERATIVE COLITIS, IRRITABLE BOWEL DISEASE AND ASTHMA | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | claimed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | claimed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | claimed |
| US-6506876-B1 | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. | 2003-01-14 | — | — | US | disclosed |
| EP-0804427-B1 | LTA4 HYDROLASE INHIBITORS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1221441-A2 | LTA4 Hydrolase inhibitors | G.D. SEARLE & CO. (US) | 2002-07-10 | — | — | EP | disclosed |
| EP-0804427-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0786992-A2 | LTA 4? HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5585492-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES WHICH ARE MEDIATED BY LTB4 PRODUCTION, SUCH AS PSORIASIS, ULCERATIVE COLITIS, IRRITABLE BOWEL DISEASE AND ASTHMA | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |